Conagra Brands, Inc. (CAG) Is Removing Synthetic Dyes From Its Food, Says Jim Cramer
Conagra Brands, Inc. (NYSE:CAG) is one of the .
Conagra Brands, Inc. (NYSE:CAG) is an embattled food products company whose shares have lost 26% year-to-date. The stock has struggled due to a multitude of factors. These include analyst downgrades stemming from high meat prices expected to affect the income statement, an updated outlook that expects sales to fall by 2% in 2025, and supply chain issues leading to its earnings missing analyst estimates. Cramer's previous comments about Conagra Brands, Inc. (NYSE:CAG) have commented on the firm's ability to potentially benefit from GLP-1 drugs despite being a food company and high yields. This time around, he revealed that Conagra Brands, Inc. (NYSE:CAG) was removing synthetic dyes from its products:
'Conagra, and . . . Nestle, are all taking the dyes out. The synthetic dyes.'
A worker assembling a meal in a food production facility.
Previously, Cramer commented on Conagra Brands, Inc. (NYSE:CAG)'s yield ahead of its earnings:
'Thursday's quiet on the Washington front but it's a good prelude to the beginning of earnings season. Conagra reports, okay, and the last time we heard from this package fruit company was a bit dispiriting. One look at that yield north of 5% tells you that something's very awry here.'
While we acknowledge the potential of CAG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
8 minutes ago
- Washington Post
Nations are meeting to drum up trillions to combat poverty — but the US isn't going
UNITED NATIONS — Many of the world's nations are gathering starting Monday in Spain for a high-level conference to tackle the growing gap between rich and poor nations and try to drum up trillions of dollars needed to close it. The United States, previously a major contributor, pulled its participation, so finding funding will be tough.
Yahoo
9 minutes ago
- Yahoo
Investing in Warteck Invest (VTX:WARN) a year ago would have delivered you a 24% gain
The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking market-beating companies to own shares in. For example, the Warteck Invest AG (VTX:WARN) share price is up 20% in the last 1 year, clearly besting the market return of around 0.2% (not including dividends). So that should have shareholders smiling. Zooming out, the stock is actually down 8.6% in the last three years. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the last year Warteck Invest grew its earnings per share (EPS) by 27%. This EPS growth is significantly higher than the 20% increase in the share price. Therefore, it seems the market isn't as excited about Warteck Invest as it was before. This could be an opportunity. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). We know that Warteck Invest has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Warteck Invest will grow revenue in the future. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Warteck Invest's TSR for the last 1 year was 24%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments! We're pleased to report that Warteck Invest shareholders have received a total shareholder return of 24% over one year. And that does include the dividend. That's better than the annualised return of 3% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Warteck Invest (of which 1 shouldn't be ignored!) you should know about. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Swiss exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Middle Eastern Penny Stocks: 3 Picks With Market Caps As Low As US$100M
As Gulf shares rise with the Israel-Iran ceasefire holding and Dubai's index reaches a 17-year high, the Middle Eastern market is experiencing a period of renewed optimism. For investors willing to explore beyond the well-known stocks, penny stocks—often representing smaller or newer companies—remain an intriguing option. Despite being considered outdated by some, these stocks can offer unique growth potential when backed by strong financials and solid fundamentals. Name Share Price Market Cap Financial Health Rating Menara Ventures Xl - Limited Partnership (TASE:MNRA) ₪2.625 ₪12.06M ★★★★★★ Thob Al Aseel (SASE:4012) SAR4.04 SAR1.64B ★★★★★★ Amanat Holdings PJSC (DFM:AMANAT) AED1.07 AED2.64B ★★★★★☆ Alarum Technologies (TASE:ALAR) ₪4.722 ₪314.37M ★★★★★★ E7 Group PJSC (ADX:E7) AED1.12 AED2.28B ★★★★★★ Katmerciler Arac Üstü Ekipman Sanayi ve Ticaret (IBSE:KATMR) TRY1.83 TRY1.97B ★★★★★☆ Dubai National Insurance & Reinsurance (P.S.C.) (DFM:DNIR) AED3.14 AED386.93M ★★★★★★ Dubai Investments PJSC (DFM:DIC) AED2.52 AED10.76B ★★★★☆☆ Sharjah Cement and Industrial Development (PJSC) (ADX:SCIDC) AED0.846 AED515.19M ★★★★★★ Tgi Infrastructures (TASE:TGI) ₪2.53 ₪188.01M ★★★★★★ Click here to see the full list of 79 stocks from our Middle Eastern Penny Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Sharjah Cement and Industrial Development Co. (ADX:SCIDC) operates in the cement manufacturing industry, with a market cap of AED 515.19 million. Operations: The company generates revenue primarily from its manufacturing segment, amounting to AED 690.53 million. Market Cap: AED515.19M Sharjah Cement and Industrial Development Co. has demonstrated robust financial performance with earnings growth of 98.1% over the past year, surpassing industry averages. The company's net profit margin improved to 5.6%, up from 3% last year, reflecting enhanced operational efficiency. Despite its high share price volatility, SCIDC maintains a satisfactory net debt to equity ratio of 24.8%, and its interest payments are well-covered by EBIT at five times coverage, indicating sound financial health. However, the board's average tenure is only 1.4 years, which may suggest potential governance challenges in terms of experience and stability. Jump into the full analysis health report here for a deeper understanding of Sharjah Cement and Industrial Development (PJSC). Assess Sharjah Cement and Industrial Development (PJSC)'s previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Ajman Bank PJSC offers a range of banking products and services to individuals, businesses, and government institutions in the United Arab Emirates, with a market capitalization of AED3.92 billion. Operations: The company generates revenue through its Treasury operations (AED113.94 million), Consumer Banking (AED266.56 million), and Wholesale Banking (AED454.45 million) segments, with a total segment adjustment of AED4.59 million. Market Cap: AED3.92B Ajman Bank PJSC has recently achieved profitability, marking a significant shift in its financial trajectory. The bank's net income for Q1 2025 was AED134.68 million, indicating improved earnings compared to the previous year. Despite this positive development, Ajman Bank faces challenges such as a high level of non-performing loans at 10.8%, which could impact future stability. The bank's return on equity is relatively low at 13.9%, and it maintains an appropriate loans-to-deposits ratio of 67%. Recent executive changes aim to bolster digital transformation efforts, potentially enhancing customer engagement and operational efficiency in the long term. Navigate through the intricacies of Ajman Bank PJSC with our comprehensive balance sheet health report here. Learn about Ajman Bank PJSC's historical performance here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Akfen Gayrimenkul Yatirim Ortakligi A.S. operates as a real estate investment trust, having restructured from Aksel Turizm Yatirimlari ve Isletmecilik AS, with a market cap of TRY9.36 billion. Operations: The company generates revenue primarily from its real estate investments, totaling TRY1.18 billion. Market Cap: TRY9.36B Akfen Gayrimenkul Yatirim Ortakligi A.S. has demonstrated robust earnings growth, with a 54% increase over the past year, surpassing industry averages. The company's debt is well-managed, with operating cash flow covering 21.4% of its debt and interest payments covered 89.6 times by EBIT. Despite this financial strength, short-term assets of TRY4.5 billion do not cover long-term liabilities of TRY6.5 billion, presenting a potential risk factor. Recent earnings for Q1 2025 showed net income rising to TRY727 million from TRY360 million the previous year, highlighting strong profitability despite slightly lower sales figures compared to last year. Click here and access our complete financial health analysis report to understand the dynamics of Akfen Gayrimenkul Yatirim Ortakligi. Understand Akfen Gayrimenkul Yatirim Ortakligi's track record by examining our performance history report. Click this link to deep-dive into the 79 companies within our Middle Eastern Penny Stocks screener. Seeking Other Investments? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ADX:SCIDC DFM:AJMANBANK and IBSE:AKFGY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
